EU Stakeholders Form New Pharma Supply Chain Verification Organization


From DCAT Value Chain Insights (VCI)

By Regulatory News posted 03-08-2015 21:10

  

The European Federation of Pharmaceutical Industries and Associations (EFPIA), the European Generic medicines Agency (EGA), the Pharmaceutical Group of the European Union (PEGU), the European Association of Pharmaceutical Full-line Wholesalers (GIRP), and the European Association of Euro-Pharmaceutical Companies (EAEPC) have formed the European Medicines Verification Organization (EMVO) as a not-for-profit stakeholder organization based in Luxembourg as a tool to combat the emergence of falsified medicines in the European Union's (EU) legitimate pharmaceutical supply chain. EMVO was formed to put forth a dependable and secure pharmaceutical verification system that can be used to implement measures of the EU Falsified Medicines Directive to ensure a safe and secure pharmaceutical supply chain in the EU. 

Financed in the initial stages by the pharmaceutical industry, EMVO will now assume responsibility for the European Hub, which links national verification systems throughout Europe, a design agreed by the European stakeholders. Through the engagement of the whole pharmaceutical supply chain, the EMVO will reinforce the value of the European Stakeholder Model allowing end-to-end verification of medicine packs from the point of manufacture, through wholesale distributors carrying out risk- based verification and pharmacies to the dispensing point for patients, thereby securing the entire supply chain.

Germany will be the first EU member state to contribute fully to the improved Europe-wide verification system under the auspices of EMVO, through its securPharm system. Meanwhile, countries that will need to comply with the EU Falsified Medicines Directive can benefit from the opportunity to join an existing product verification infrastructure designed by the EMVO (referred to as the national Blueprint System Template).

Newly-appointed EMVO Spokesman John Chave said: “The establishment of the EMVO is a major milestone in the implementation of the Falsified Medicines Directive, and shows stakeholders in the pharmaceutical sector working together to improve the security of the legitimate supply chain and, most importantly, to promote patient safety."

EFPIA represents 33 national associations and the leading research-based pharmaceutical companies in Europe. The EGA represents the generic drug and biosimilar industries in Europe. PEGU represents the national associations and professional bodies of community pharmacists in 34 European countries including EU member states. GIRP is the umbrella organization of pharmaceutical full-line wholesalers in Europe. It represents the national associations of over 750 pharmaceutical full-line wholesalers serving 32 European countries, including major Pan-European pharmaceutical full-line wholesaling companies. EAEPC represents national associations and individual companies in pharmaceutical parallel distribution in Europe. EAEPC members handle about 70% of the volume of parallel imports in the European Economic Area.

Source: EGA

0 comments
94 views


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription 

Permalink